1. Society of Neuroscience Holds Conference in San Diego

    Society of Neuroscience Holds Conference in San Diego
    Innovative Discoveries: Science Presented at Neuroscience 2016 Neuroscience 2016 took place November 12-16 at the San Diego Convention Center. The Society for Neuroscience's 46th annual meeting is the premier venue for neuroscientists to meet, present emerging science, learn from experts, collaborate with peers, explore new tools and technologies, and advance careers. There were more than 30,000 colleagues from more than...
  2. Treating Cancer Using Epirubicidin

    MECHANISM OF ACTION: epirubicidin, anthracycline, antibiotics, anticancerThe mechanism of action of epirubicin appears to be related to its ability to bind to nucleic acids. It forms a complex with DNA by intercalation between base pairs, resulting in inhibition of DNA and RNA synthesis. Intercalation also triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity.
  3. Doxorubicin in Cancer Chemotherapy

    Doxorubicin; trade name Adriamycin; also known as hydroxydaunorubicin, is a drug used in cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA, while most serious adverse effect being life-threatening heart damage.
  4. Puromycin: Somatic Cell Cloning

    Puromycin N-acetyl transferase gene (pac), of which the gene product catalyzes antibiotic puromycin, an effective inhibitor of protein synthesis, has been widely used as a dominant selection marker in embryonic stem (ES) cell-mediated transgenesis.
  5. Hygromycin B: Selective Properties

    Hygromycin B is an antibiotic used by scientists in bio-research to select cells modified by genetic engineering. It inhibits the growth of a wide range of prokaryotic and eukaryotic cells by interfering with protein synthesis. Hygromycin B allows the selection and maintenance of cells expressing the hygromycin-resistance gene.
  6. MG-132: Fighting Cancer Cells

    Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent because it induces apoptosis in cancer cells but not in normal cells.
  7. Proteasome Inhibitor MG132 Induces Death Receptor

    Combined treatment with a proteasome inhibitor and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a promising strategy for cancer therapy.
  8. Want to see your genome on a smartphone?

    Portable Genomics, a new La Jolla startup, is seeking investors to help underwrite its plan to commercially develop software that can display a person's genetic information on such devices as smartphones and electronic tablets.
  9. Innovator Tracks Everything His Body Does

    Larry Smarr stops a visitor and says, “Before you go, let me show you my stool sample.” The UC San Diego physicist-futurist reaches into his kitchen refrigerator, past the milk, and pulls out a small white box. He marvels over its contents. “The bacteria in here contains more info than you’d find on a computer chip,” Smarr says. “It’s a window into your health. Within 10 years, people won’t dream of going to a doctor without first getting a sample like this.” Feeling squeamish? Smarr can have that effect on people. Virtually nothing is out-of-bounds these days when he promotes the “Quantified Self,” an emerging movement in which people use biosensors and other gadgets to closely monitor their bodies in the name of wellness.

9 Item(s)

To Top